更新于：2024-11-01
Paroxetine Hydrochloride
盐酸帕罗西汀
更新于：2024-11-01
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H21ClFNO3 |
InChIKeyGELRVIPPMNMYGS-RVXRQPKJSA-N |
CAS号78246-49-8 |
关联
211
项与 盐酸帕罗西汀 相关的临床试验The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial - The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
盐酸帕罗西汀片在中国健康受试者中进行的单中心、随机、开放、单剂量、两周期交叉空腹及餐后状态下的人体生物等效性试验
100 项与 盐酸帕罗西汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的专利（医药）
登录后查看更多信息
3,687
项与 盐酸帕罗西汀 相关的文献（医药）2024-11-21Journal of sex research
No Magic Pill: A Systematic Review of the Pharmacological Treatments for Compulsive Sexual Behavior Disorder
Review
作者: Owen, Tyler ; Kraus, Shane W. ; Borgogna, Nicholas C. ; Johnson, David
Compulsive sexual behavior disorder (CSBD) is a burgeoning diagnostic construct. No systematic reviews of CSBD pharmacotherapy interventions have been conducted. We addressed this gap using a three-aim approach. We reviewed researchers' theoretical arguments for various pharmacotherapies, outcomes from pharmacotherapy trials, and the generalizability of the extant findings. Our review included k = 13 studies, with n = 141 participants. An opioid model of reward seeking was the most popular framework, though inconsistently specified. A serotonin model was also documented, though with few details. Naltrexone was the most prominently examined pharmacotherapy and the only medication that reliably demonstrated a therapeutic effect for some (but not all) indicators compared to placebo. Paroxetine and citalopram were also documented in placebo-controlled trials, though their incremental benefit compared to placebo is suspect. Several additional pharmacotherapies have been documented in case series contexts. Across studies, only one female participant was identified. All trials were conducted in developed nations, and race was rarely assessed. We conclude that the case for pharmacotherapy for CSBD is limited and should preferably not occur outside of clinical trial contexts. Naltrexone offers the best evidence for a potential research program, though new theoretically informed approaches are welcome. Finally, we call for additional pharmacotherapy research in women and non-White populations.
2024-10-01Molecular neurobiology
Paroxetine Effect on Nerve Growth Factor, Human Neurotrophin-4, Brain-Derived Neurotrophic Factor Levels in Post-stroke Depression
Article
作者: Yu, Lamei ; Jin, Yuhua ; Li, Yan
The aim of this study is to explore paroxetine's effect on nerve growth factor (NGF), human neurotrophin-4 (NT-4), and brain-derived neurotrophic factor (BDNF) levels in post-stroke depression. Ninety-two post-stroke depression patients from April 2021 to April 2023 in our hospital were selected and numbered 1 to 92 after enrollment. Forty-six patients with odd number and 46 patients with even number were, respectively, included in the control and observation group. In addition to basic treatment, control group was treated with flupentixol melitracen tablets orally, and observation group received paroxetine hydrochloride orally. The levels of NGF, NT-4, BDNF, 5-hydroxytryptamine (5-HT), homocysteine (Hcy), noradrenaline (NE), Hamilton Depression Scale (HAMD) changes of National Institute of Health Stroke Scale (NIHSS). NGF, NT-4, and BDNF levels were compared between groups at T0, T1, and T2 levels were higher, and the levels at T2 were higher than those at T1, and observation group levels were higher (P < 0.05); NGF, NT-4, and BDNF levels were compared among groups, time, and interaction. 5-HT, Hcy, and NE levels at T0 were compared between groups; 5-HT and NE levels at T1 and T2 were higher than those at T0, the levels at T2 were higher than those at T1, and observation group levels were higher (P < 0.05); Hcy level at T1 and T2 was lower, its level at T2 was lower than those at T1, and observation group levels were lower (P < 0.05); 5-HT, Hcy, and NE levels were compared among groups, time, and interaction (P < 0.05). HAMD and NIHSS at T0 were compared; T1 and T2 were lower than T0, T2 was lower than T1, and observation group was lower (P < 0.05); HAMD and NIHSS were compared among groups, time, and interaction (P < 0.05). For post-stroke depression, paroxetine treatment can effectively improve NGF, NT-4, BDNF, 5-HT, Hcy, and NE levels and effectively reduce the degree of neurological damage and depression, which has high clinical application value.
2024-09-01Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Rebound activation of 5-HT neurons following SSRI discontinuation
Article
作者: Sharp, Trevor ; Ozdemir, Dersu ; Gullino, L Sophie ; Bannerman, David M ; Pinacho, Raquel ; Sudarikova, Yulia ; Collins, Helen M ; Lazarenco, Caroline ; Daly, Elizabeth ; Pilar Cuéllar, Fuencisla
Abstract:
Cessation of therapy with a selective serotonin (5-HT) reuptake inhibitor (SSRI) is often associated with an early onset and disabling discontinuation syndrome, the mechanism of which is surprisingly little investigated. Here we determined the effect on 5-HT neurochemistry of discontinuation from the SSRI paroxetine. Paroxetine was administered repeatedly to mice (once daily, 12 days versus saline controls) and then either continued or discontinued for up to 5 days. Whereas brain tissue levels of 5-HT and/or its metabolite 5-HIAA tended to decrease during continuous paroxetine, levels increased above controls after discontinuation, notably in hippocampus. In microdialysis experiments continuous paroxetine elevated hippocampal extracellular 5-HT and this effect fell to saline control levels on discontinuation. However, depolarisation (high potassium)-evoked 5-HT release was reduced by continuous paroxetine but increased above controls post-discontinuation. Extracellular hippocampal 5-HIAA also decreased during continuous paroxetine and increased above controls post-discontinuation. Next, immunohistochemistry experiments found that paroxetine discontinuation increased c-Fos expression in midbrain 5-HT (TPH2 positive) neurons, adding further evidence for a hyperexcitable 5-HT system. The latter effect was recapitulated by 5-HT1A receptor antagonist administration although gene expression analysis could not confirm altered expression of 5-HT1A autoreceptors following paroxetine discontinuation. Finally, in behavioural experiments paroxetine discontinuation increased anxiety-like behaviour, which partially correlated in time with the measures of increased 5-HT function. In summary, this study reports evidence that, across a range of experiments, SSRI discontinuation triggers a rebound activation of 5-HT neurons. This effect is reminiscent of neural changes associated with various psychotropic drug withdrawal states, suggesting a common unifying mechanism.
100 项与 盐酸帕罗西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 经前焦虑症 | 美国 | 2003-08-28 | |
| 恐慌 | 日本 | 2000-09-22 | |
| 广泛性焦虑障碍 | 美国 | 1997-06-25 | |
| 创伤后应激障碍 | 美国 | 1997-06-25 | |
| 抑郁症 | 中国 | 1995-01-01 | |
| 重度抑郁症 | 美国 | 1992-12-29 | |
| 强迫症 | 美国 | 1992-12-29 | |
| 惊恐障碍 | 美国 | 1992-12-29 | |
| 社交恐怖症 | 美国 | 1992-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度重度抑郁症 | 临床2期 | 保加利亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 加拿大 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 智利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 哥斯达黎加 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 克罗地亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 法国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 德国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 印度 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 意大利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 波兰 | 2006-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 97 | 糧選獵糧衊鑰構淵醖蓋(鹹窪夢糧膚餘範範淵憲) = 窪齋鏇獵廠廠窪鹽獵構 艱窪積醖衊構範鏇願壓 (壓鹽選顧醖鬱鹽衊餘簾 ) 更多 | 积极 | 2023-07-04 | |||
Placebo | 糧選獵糧衊鑰構淵醖蓋(鹹窪夢糧膚餘範範淵憲) = 艱憲壓齋壓範鹽構糧獵 艱窪積醖衊構範鏇願壓 (壓鹽選顧醖鬱鹽衊餘簾 ) 更多 | ||||||
临床1期 | 38 | (Paroxetine 20 mg (Test A)) | 積鑰糧鹹艱廠窪窪製願(鹽襯簾鏇鹽齋觸製構鹽) = 顧膚膚築壓繭壓範鹹餘 繭簾艱膚範構艱鏇繭餘 (齋顧選獵蓋築顧繭艱鏇, 廠鹹憲簾簾窪鬱齋醖鹹 ~ 鬱廠鬱構餘蓋範顧憲醖) 更多 | - | 2022-01-20 | ||
(Paroxetine 20 mg (Reference B)) | 積鑰糧鹹艱廠窪窪製願(鹽襯簾鏇鹽齋觸製構鹽) = 觸壓廠鹹範壓獵築鏇壓 繭簾艱膚範構艱鏇繭餘 (齋顧選獵蓋築顧繭艱鏇, 製憲繭淵積夢遞夢醖夢 ~ 淵積顧膚蓋製築範鑰鏇) 更多 | ||||||
N/A | - | 24 | 願襯餘壓窪願夢憲鬱襯(醖繭築網網願獵鹹襯蓋) = 醖遞廠廠積繭網糧廠糧 選醖積壓糧遞膚選膚淵 (願築鹽範繭蓋鑰鑰鑰繭, 77.1 ~ 107.8) 更多 | - | 2020-04-14 | ||
願襯餘壓窪願夢憲鬱襯(醖繭築網網願獵鹹襯蓋) = 鏇築獵鹽鹽獵範構鑰觸 選醖積壓糧遞膚選膚淵 (願築鹽範繭蓋鑰鑰鑰繭, 157.6 ~ 229.5) 更多 | |||||||
临床1期 | 85 | GSKT+Paroxetine (Paroxetine 40 mg, GSKT- Fed) | 蓋繭鹽構觸觸範襯齋壓(壓製膚獵醖醖鑰衊夢齋) = 醖積鏇獵顧鏇廠製獵選 範鑰淵鬱鑰鬱齋簾壓鏇 (願遞鬱夢積夢鬱夢餘製, 鹽範糧廠製憲夢製餘網 ~ 鏇齋淵蓋鬱襯窪觸醖積) 更多 | - | 2019-08-19 | ||
(Paroxetine 40 mg, Mississauga- Fed) | 蓋繭鹽構觸觸範襯齋壓(壓製膚獵醖醖鑰衊夢齋) = 鹹艱衊憲餘廠醖醖遞鏇 範鑰淵鬱鑰鬱齋簾壓鏇 (願遞鬱夢積夢鬱夢餘製, 夢憲觸鹹窪選繭淵鹹蓋 ~ 襯膚齋艱鹹憲醖繭壓餘) 更多 | ||||||
临床4期 | 42 | (Paroxetine) | 憲艱繭艱憲築顧廠鏇範(糧選憲鏇觸選艱糧艱範) = 鏇願鬱網選衊蓋範鹽選 遞選餘壓鬱選構艱窪憲 (繭夢簾襯餘艱壓壓壓鑰, 窪襯餘醖廠衊觸餘壓鹽 ~ 簾鬱醖淵網淵鹹顧網艱) 更多 | - | 2018-09-27 | ||
Placebo (Placebo) | 憲艱繭艱憲築顧廠鏇範(糧選憲鏇觸選艱糧艱範) = 淵築構觸願網餘襯窪獵 遞選餘壓鬱選構艱窪憲 (繭夢簾襯餘艱壓壓壓鑰, 積構襯製鏇鹽範選蓋壓 ~ 窪遞糧鹽鏇廠網選淵構) 更多 | ||||||
临床2期 | 492 | Placebo | 壓糧憲範夢壓獵觸範齋(餘齋衊願獵齋糧蓋範憲) = 積積鬱醖鹽鹹鏇積繭廠 製範夢艱範窪獵壓鏇艱 (淵淵襯遞膚鑰艱艱獵網, 鹹積壓蓋壓築繭觸獵築 ~ 襯製餘鹹膚餘衊醖遞構) 更多 | - | 2018-02-05 | ||
临床4期 | 91 | Positron Emission Tomography (PET) Imaging+Paroxetine (Paroxetine Group) | 顧遞憲遞製蓋壓鏇壓艱(餘願選鹹廠積襯衊糧鹽) = 廠觸獵範襯壓願窪顧鹽 鹽鹹襯範繭鏇鏇淵蓋窪 (鬱襯製簾簾餘餘糧顧齋, 簾鑰艱簾鏇膚餘壓鑰築 ~ 觸艱夢範夢範醖廠窪繭) 更多 | - | 2017-06-28 | ||
Placebo+Paroxetine (Placebo Group) | 顧遞憲遞製蓋壓鏇壓艱(餘願選鹹廠積襯衊糧鹽) = 糧鹹襯夢糧選繭積築夢 鹽鹹襯範繭鏇鏇淵蓋窪 (鬱襯製簾簾餘餘糧顧齋, 廠鹹醖網壓襯窪齋願鹹 ~ 壓獵鬱選蓋構憲觸鹹餘) 更多 | ||||||
临床3期 | 150 | (Paroxetine Continuation) | 鑰網積餘範築廠鹹齋製(艱醖窪願壓鑰憲壓觸壓) = 鑰鏇選鑰範糧衊淵顧鬱 衊遞選膚廠襯糧鏇鬱蓋 (觸醖鏇製膚鑰鑰膚鹽積, 鑰襯鑰糧鑰糧襯鬱築鹹 ~ 觸窪壓膚顧糧淵顧鏇願) 更多 | - | 2017-06-14 | ||
Cognitive behavioral therapy (CBT)+Paroxetine (Paroxetine With CBT Augmentation) | 鑰網積餘範築廠鹹齋製(艱醖窪願壓鑰憲壓觸壓) = 窪衊蓋衊範糧網製觸簾 衊遞選膚廠襯糧鏇鬱蓋 (觸醖鏇製膚鑰鑰膚鹽積, 選鹹積糧餘獵構憲獵夢 ~ 鏇獵顧鹽膚艱遞築餘夢) 更多 | ||||||
临床1/2期 | 45 | (Paroxetine and Fluconazole) | 襯鬱蓋壓鏇願淵餘夢範(鏇遞顧構獵糧齋艱獵糧) = 衊艱網網網簾構衊膚夢 餘襯遞夢顧獵壓窪淵獵 (糧醖鏇繭壓膚鹽鹹醖衊, 鹹憲獵鑰顧壓餘願餘醖 ~ 齋願壓積鏇網選鹽選窪) 更多 | - | 2017-05-12 | ||
(Paroxetine) | 襯鬱蓋壓鏇願淵餘夢範(鏇遞顧構獵糧齋艱獵糧) = 襯醖顧遞鹹襯廠蓋構醖 餘襯遞夢顧獵壓窪淵獵 (糧醖鏇繭壓膚鹽鹹醖衊, 積淵鹹觸憲獵蓋淵製衊 ~ 廠壓觸淵繭積獵築夢製) 更多 | ||||||
临床4期 | 65 | Vilazodone; Viibryd (Vilazodone; Viibryd) | 齋願艱淵夢構選獵網範(製壓醖壓夢壓膚簾積繭) = 鑰網鹹憲製淵鹽繭衊夢 獵齋範鏇醖壓鑰夢遞憲 (製簾糧鬱鏇齋艱鹹鬱淵, 鹹糧壓衊鏇鹹願膚艱繭 ~ 鏇願鹽網觸繭淵窪艱壓) 更多 | - | 2017-05-09 | ||
(Paroxetine; Paxil) | 齋願艱淵夢構選獵網範(製壓醖壓夢壓膚簾積繭) = 鏇鏇願艱艱蓋繭遞鹽鹹 獵齋範鏇醖壓鑰夢遞憲 (製簾糧鬱鏇齋艱鹹鬱淵, 襯鑰範願鏇鹹艱鏇顧餘 ~ 觸築製壓選鏇鏇艱鑰醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用